CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the election of Steven M. Paul, M.D., to its Board of Directors. Dr. Paul is the former President of the Lilly Research Laboratories of Eli Lilly and Company. Alnylam also announced the retirement of James L. Vincent, the former Chief Executive Officer and Chairman of Biogen Idec, Inc.
